EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Immunogenicity of COVID ‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy

Yeong Jer Lim iD, Victoria Ward, Anthony Brown, Eloise Phillips, Barbara Kronsteiner, Tom Malone, Daisy Jennings, Saoirse Healy, Stephanie Longet, Timothy James, Paul Thomson, Liam Farrell und 18 weitere

British Journal of Haematology · 2024-08 · 205 (2) · 440-451

DOI: 10.1111/bjh.19562 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift British Journal of Haematology, online erschienen am 13.06.2024. Verfasst von Yeong Jer Lim und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Bendamustine Hydrochloride, COVID-19, Lymphoma, Follicular. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Department of Health and Social Care, Medical Research Council, Huo Family Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune responses to primary COVID‐19 vaccination were investigated in 58 patients with follicular lymphoma (FL) as part of the PETReA trial of frontline therapy (EudraCT 2016–004010‐10). COVID‐19 vaccines (BNT162b2 or ChAdOx1) were administered before, during or after cytoreductive treatment comprising rituximab (depletes B cells) and either bendamustine (depletes CD4 + T cells) or cyclophosphamide‐based chemotherapy. Blood samples obtained after vaccine doses 1 and 2 (V1, V2) were analysed for antibodies and T cells reactive to the SARS‐CoV‐2 spike protein using the Abbott Architect and interferon‐gamma ELISpot assays respectively. Compared to 149 healthy controls, patients with FL exhibited lower antibody but preserved T‐cell responses. Within the FL cohort, multivariable analysis identified low pre‐treatment serum IgA levels and V2 administration during induction or maintenance treatment as independent determinants of lower antibody and higher T‐cell responses, and bendamustine and high/intermediate FLIPI‐2 score as additional determinants of a lower antibody response. Several clinical scenarios were identified where dichotomous immune responses were estimated with >95% confidence based on combinations of predictive variables. In conclusion, the immunogenicity of COVID‐19 vaccines in FL patients is influenced by multiple disease‐ and treatment‐related factors, among which B‐cell depletion showed differential effects on antibody and T‐cell responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bendamustine HydrochlorideCOVID-19Lymphoma, FollicularAdultAgedFemaleHumansMaleMiddle AgedAntibodies, ViralAntineoplastic Combined Chemotherapy ProtocolsBNT162 VaccineCOVID-19 VaccinesCyclophosphamideImmunogenicity, VaccineImmunotherapyRituximabSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

COVID19follicular lymphomalymphoid malignanciestherapyvaccination

Substanzen

Antibodies, ViralBendamustine HydrochlorideBNT162 VaccineCOVID-19 VaccinesCyclophosphamideRituximabSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
  • The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.
  • Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Department of Medical Microbiology and Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Department of Clinical Biochemistry, John Radcliffe Hospital, Oxford, UK.
  • Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, UK.

ORCID-Profile: Yeong Jer Lim, Toby A Eyre, Andrew Pettitt

Förderung

  • UK Department of Health and Social Care
  • Medical Research Council
  • Huo Family Foundation
  • Cancer Research UK
  • MRC/UKRI
  • Wellcome Trust
  • National Institute for Health and Care Research
  • Blood Cancer UK

Zitieren

APA

Lim, Y. J., Ward, V., Brown, A., Phillips, E., Kronsteiner, B., Malone, T., Jennings, D., Healy, S., Longet, S., James, T., Thomson, P., Farrell, L., Oates, M., Jackson, R., Morrison, A., Burns, M., Carroll, M., Klenerman, P., Turtle, L., …, & Pettitt, A. (2024). Immunogenicity of COVID ‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. British Journal of Haematology, 205(2), 440-451. https://doi.org/10.1111/bjh.19562

Vancouver

Lim YJ, Ward V, Brown A, Phillips E, Kronsteiner B, Malone T, et al. Immunogenicity of COVID ‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. British Journal of Haematology. 2024;205(2):440-451. doi:10.1111/bjh.19562

BibTeX
@article{Lim2024,
  author = {Lim, Yeong Jer and Ward, Victoria and Brown, Anthony and Phillips, Eloise and Kronsteiner, Barbara and Malone, Tom and Jennings, Daisy and Healy, Saoirse and Longet, Stephanie and James, Timothy and Thomson, Paul and Farrell, Liam and Oates, Melanie and Jackson, Richard and Morrison, Andrew and Burns, Matthew and Carroll, Miles and Klenerman, Paul and Turtle, Lance and Naisbitt, Dean and Rhodes, Malcolm and Robinson, Kate and Gatto, Simona and Young, Moya and Linton, Kim and Eyre, Toby A and Eyre, David W and Dunachie, Susanna and Barnes, Eleanor and Pettitt, Andrew},
  title = {Immunogenicity of COVID ‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {205},
  number = {2},
  pages = {440--451},
  doi = {10.1111/bjh.19562}
}
Kostenlos starten →